BSL-23: Measuring Borderline Symptom Severity and Treatment Progress
Borderline personality disorder (BPD) is one of the most clinically challenging conditions to treat, and to measure. The emotional instability, interpersonal chaos, and identity disturbance that characterize BPD don't map cleanly onto the scales designed for mood and anxiety disorders. A patient with BPD might score moderately on the PHQ-9 while experiencing profound suffering that the instrument simply doesn't capture.
The Borderline Symptom List (BSL-23) was developed specifically to fill this measurement gap. It's a 23-item self-report measure that captures the subjective experience of borderline symptoms, making it one of the few validated instruments designed to track BPD severity and treatment response over time.
What Makes the BSL-23 Different
Most personality disorder assessments are diagnostic instruments: they determine whether someone meets criteria. The BSL-23 does something different: it measures severity of the borderline experience over the past week. This makes it responsive to change and suitable for repeated administration during treatment.
The items capture the lived experience of BPD in ways that generic distress measures miss:
- Emotional pain and inner emptiness
- Feelings of loneliness, self-contempt, and disgust
- Distrust of others
- Urges for self-harm
- Dissociative experiences
- Difficulty controlling emotions
- Feelings of being overwhelmed by emotions
Patients with BPD often report that the BSL-23 "gets it" in ways that depression and anxiety questionnaires don't. This recognition itself has therapeutic value. It communicates that you understand their specific suffering.
Scoring and Interpretation
Items are scored 0–4 (not at all to very strong). The total score is the mean of all 23 items, ranging from 0 to 4.
Severity guidelines:
- 0–0.3: No/low borderline symptomatology
- 0.3–0.7: Mild
- 0.7–1.5: Moderate
- 1.5–2.5: Severe
- 2.5+: Very severe
A change of 0.3 or more in the mean score represents reliable change.
Clinical Value in Treatment
BPD treatment is typically long-term, and both patients and therapists need ways to track whether things are moving in the right direction. The BSL-23 fills this need in several ways.
Weekly pulse on emotional experience. BPD involves rapid emotional shifts, and a patient's presentation in session may not represent their week. The BSL-23 provides a broader picture by asking about the past seven days, capturing crises, dissociative episodes, and emotional pain that may not emerge in a single session conversation.
Sensitivity to specific BPD changes. DBT (dialectical behavior therapy) aims to reduce emotional dysregulation, self-harm urges, and identity disturbance. The BSL-23 measures exactly these constructs, making it more sensitive to DBT-specific improvements than generic measures. A patient might show significant BSL-23 improvement while their PHQ-9 barely moves, because the PHQ-9 isn't measuring what's actually changing.
Tracking beyond crisis reduction. BPD treatment often succeeds first in reducing crisis behaviors (self-harm, suicidal gestures, emergency visits). The BSL-23 captures improvement in the subjective emotional experience (inner emptiness, self-contempt, emotional overwhelm) that continues long after crisis behaviors have reduced.
Validating the patient's experience. For patients with BPD, who often feel misunderstood or dismissed, a declining BSL-23 score provides concrete evidence that their experience is improving. This can be powerfully validating, especially during phases of treatment where progress feels invisible.
When to Use the BSL-23
As a primary outcome measure in BPD treatment. If you're providing DBT, MBT, schema therapy, or other BPD-focused treatment, the BSL-23 should be your core tracking instrument.
As a supplement to general measures. If you're using the PHQ-9 or CORE-OM as your primary outcome measures, adding the BSL-23 for patients with BPD captures the BPD-specific dimension that general measures miss.
For differential assessment. A patient presenting with depression and emotional instability might score similarly on the PHQ-9 whether the underlying condition is major depressive disorder or BPD. The BSL-23 helps differentiate: elevated BSL-23 scores alongside depression symptoms suggest BPD features that should inform treatment planning.
At treatment milestones. Administering the BSL-23 at the beginning and end of each treatment phase (e.g., individual therapy stage of DBT, each module of schema therapy) provides stage-specific outcome data.
Practical Considerations
Frequency of administration. Weekly administration aligns well with the BSL-23's one-week reference period and with the weekly rhythm of most BPD-focused treatments. For less intensive treatment, fortnightly works well.
Handling high-risk items. The BSL-23 includes items about self-harm urges and feelings that life is not worth living. As with any assessment containing risk items, establish a protocol for reviewing responses promptly and following up on elevated risk items.
Discussing scores with patients with BPD. Transparent score sharing is particularly valuable (and particularly delicate) with this population. BPD involves difficulty with emotional regulation, and a score that hasn't improved, or has worsened, can trigger intense reactions. Frame the data as information, not judgment: "Your score went up this week. That tells us something important about what you experienced. Let's look at what happened."
Avoid using scores as behavioral contingencies. Don't imply that the patient should "try" to lower their score, or express disappointment when scores are high. The BSL-23 measures experience, not effort. The goal is honest reporting, which requires the patient to feel safe reporting truthfully.